Association between nonalcoholic fatty liver disease and Helicobacter pylori infection in Dali City, China

References

1. 1.↵
   1. Loomba R,
   2. Lim JK,
   3. Patton H,
   4. El-Serag HB.

   AGA Clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: Expert review. Gastroenterology 2020; 158: 1822–1830.

   OpenUrlPubMedGoogle Scholar
2. 2.↵
   1. Zhou F,
   2. Zhou J,
   3. Wang W,
   4. Zhang XJ,
   5. Ji YX,
   6. Zhang P, et al.

   Unexpected Rapid Increase in the Burden of NAFLD in China from 2008 to 2018: A systematic review and meta-analysis. Hepatology 2019; 70: 1119–1133.

   OpenUrlCrossRefPubMedGoogle Scholar
3. 3.↵
   1. Estes C,
   2. Anstee QM,
   3. Arias-Loste MT,
   4. Bantel H,
   5. Bellentani S,
   6. Caballeria J, et al.

   Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 2018; 69: 896-904.

   Google Scholar
4. 4.↵
   1. Younossi ZM.

   Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol 2019; 70: 531-544.

   Google Scholar
5. 5.↵
   1. Safari Z,
   2. Gerard P.

   The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci 2019; 76: 1541–1558.

   OpenUrlCrossRefGoogle Scholar
6. 6.↵
   1. Mansori K,
   2. Moradi Y,
   3. Naderpour S,
   4. Rashti R,
   5. Moghaddam AB,
   6. Saed L, et al.

   Helicobacter pylori infection as a risk factor for diabetes: a meta-analysis of case-control studies. BMC Gastroenterol 2020; 20: 77.

   OpenUrlCrossRefGoogle Scholar
7. 7.↵
   1. Crowe SE.

   Helicobacter pylori Infection. N Engl J Med 2019; 380: 1158–1165.

   OpenUrlCrossRefGoogle Scholar
8. 8.↵
   1. Razuka-Ebela D,
   2. Giupponi B,
   3. Franceschi F.

   Helicobacter pylori and extragastric diseases. Helicobacter 2018; 23 Suppl 1: e12520.

   OpenUrlGoogle Scholar
9. 9.↵
   1. Zhou BG,
   2. Yang HJ,
   3. Xu W,
   4. Wang K,
   5. Guo P,
   6. Ai YW.

   Association between Helicobacter pylori infection and nonalcoholic fatty liver disease: A systematic review and meta-analysis of observational studies. Helicobacter 2019; 24: e12576.

   OpenUrlGoogle Scholar
10. 10.
    1. Yu YY,
    2. Cai JT,
    3. Song ZY,
    4. Tong YL,
    5. Wang JH.

    The associations among Helicobacter pylori infection, white blood cell count and nonalcoholic fatty liver disease in a large Chinese population. Medicine (Baltimore) 2018; 97: e13271.

    OpenUrlGoogle Scholar
11. 11.↵
    1. Jiang T,
    2. Chen X,
    3. Xia C,
    4. Liu H,
    5. Yan H,
    6. Wang G, et al.

    Association between Helicobacter pylori infection and non-alcoholic fatty liver disease in North Chinese: a cross-sectional study. Sci Rep 2019; 9: 4874.

    OpenUrlGoogle Scholar
12. 12.↵
    1. Okushin K,
    2. Takahashi Y,
    3. Yamamichi N,
    4. Shimamoto T,
    5. Enooku K,
    6. Fujinaga H, et al.

    Helicobacter pylori infection is not associated with fatty liver disease including non-alcoholic fatty liver disease: a large-scale cross-sectional study in Japan. BMC Gastroenterol 2015; 15: 25.

    OpenUrlGoogle Scholar
13. 13.↵
    1. Baeg MK,
    2. Yoon SK,
    3. Ko SH,
    4. Noh YS,
    5. Lee IS,
    6. Choi MG.

    Helicobacter pylori infection is not associated with nonalcoholic fatty liver disease. World J Gastroenterol 2016; 22: 2592–2600.

    OpenUrlGoogle Scholar
14. 14.
    1. Fan N,
    2. Peng L,
    3. Xia Z,
    4. Zhang L,
    5. Wang Y,
    6. Peng Y.

    Helicobacter pylori infection is not associated with non-alcoholic fatty liver disease: A cross-sectional study in china. front microbiol 2018; 9: 73.

    OpenUrlGoogle Scholar
15. 15.↵
    1. Cai O,
    2. Huang Z,
    3. Li M,
    4. Zhang C,
    5. Xi F,
    6. Tan S.

    Association between Helicobacter pylori infection and nonalcoholic fatty liver disease: A single-center clinical study. Gastroenterol Res Pract 2018; 2018: 8040262.

    OpenUrlGoogle Scholar
16. 16.↵
    1. Zou B,
    2. Sun L,
    3. Wang X,
    4. Chen Z.

    The prevalence of single and multiple thyroid nodules and its association with metabolic diseases in Chinese: A cross-sectional study. Int J Endocrinol 2020; 2020: 5381012.

    OpenUrlGoogle Scholar
17. 17.↵
    1. Xue Y,
    2. Zhou LY,
    3. Lu HP,
    4. Liu JZ.

    Recurrence of Helicobacter pylori infection: incidence and influential factors. Chin Med J (Engl) 2019; 132: 765–771.

    OpenUrlGoogle Scholar
18. 18.↵
    1. Friedman SL,
    2. Neuschwander-Tetri BA,
    3. Rinella M,
    4. Sanyal AJ.

    Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018; 24: 908–922.

    OpenUrlCrossRefPubMedGoogle Scholar
19. 19.↵
    1. Okushin K,
    2. Tsutsumi T,
    3. Ikeuchi K,
    4. Kado A,
    5. Enooku K,
    6. Fujinaga H, et al.

    Helicobacter pylori infection and liver diseases: Epidemiology and insights into pathogenesis. World J Gastroenterol 2018; 24: 3617–3625.

    OpenUrlGoogle Scholar
20. 20.↵
    1. Liu R,
    2. Liu Q,
    3. He Y,
    4. Shi W,
    5. Xu Q,
    6. Yuan Q, et al.

    Association between Helicobacter pylori infection and nonalcoholic fatty liver: A meta-analysis. Medicine (Baltimore) 2019; 98: e17781.

    OpenUrlCrossRefGoogle Scholar
21. 21.↵
    1. Neves C,
    2. Rodrigues T,
    3. Sereno J,
    4. Simoes C,
    5. Castelhano J,
    6. Goncalves J, et al.

    Dietary Glycotoxins Impair Hepatic Lipidemic Profile in Diet-Induced Obese Rats Causing Hepatic Oxidative Stress and Insulin Resistance. Oxid Med Cell Longev 2019; 2019: 6362910.

    OpenUrlGoogle Scholar
22. 22.↵
    1. Federico A,
    2. Zulli C,
    3. de Sio I,
    4. Del Prete A,
    5. Dallio M,
    6. Masarone M, et al.

    Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20: 16841–16857.

    OpenUrlCrossRefPubMedGoogle Scholar
23. 23.↵
    1. Chen C,
    2. Zhang C,
    3. Wang X,
    4. Zhang F,
    5. Zhang Z,
    6. Ma P, et al.

    Helicobacter pylori infection may increase the severity of nonalcoholic fatty liver disease via promoting liver function damage, glycometabolism, lipid metabolism, inflammatory reaction and metabolic syndrome. Eur J Gastroenterol Hepatol 2020; 32: 857–866.

    OpenUrlGoogle Scholar
24. 24.
    1. Alvarez CS,
    2. Florio AA,
    3. Butt J,
    4. Rivera-Andrade A,
    5. Kroker-Lobos MF,
    6. Waterboer T, et al.

    Associations between Helicobacter pylori with nonalcoholic fatty liver disease and other metabolic conditions in Guatemala. Helicobacter 2020: e12756.

    Google Scholar
25. 25.
    1. Lim SH,
    2. Kim N,
    3. Kwon JW,
    4. Kim SE,
    5. Baik GH,
    6. Lee JY, et al.

    Positive association between Helicobacter pylori infection and metabolic syndrome in a Korean population: A multicenter nationwide study. Dig Dis Sci 2019; 64: 2219–2230.

    OpenUrlGoogle Scholar
26. 26.↵
    1. Liou JM,
    2. Chen CC,
    3. Chang CM,
    4. Fang YJ,
    5. Bair MJ,
    6. Chen PY, et al.

    Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial. Lancet Infect Dis 2019; 19: 1109-1120.

    Google Scholar
27. 27.↵
    1. Shimamoto T,
    2. Yamamichi N,
    3. Gondo K,
    4. Takahashi Y,
    5. Takeuchi C,
    6. Wada R, et al.

    The association of Helicobacter pylori infection with serum lipid profiles: An evaluation based on a combination of meta-analysis and a propensity score-based observational approach. PLoS One 2020; 15: e0234433.

    OpenUrlGoogle Scholar